

AAPS Connection

American Association of Pharmaceutical Scientists

January 2011

New Year, New Opportunities

It's a new year and a great time to pursue new and exciting opportunities!



Log onto the AAPS Online Career Center to post your resume or curriculum vitae (CV) and view available openings today! AAPS's Online Career Center is free to job seekers and provides a forum to network with industry contacts and stay abreast of which employers are hiring and what current skills are in demand.

Visit <http://careers.aaps.org> for more information or to create your profile.

The 46th Annual Pharmaceutical Technologies Arden Conference: Pharmaceutical Development of Biologics: Fundamentals, Challenges, and Recent Advances

March 6–10, 2011
The Thayer Hotel
West Point, NY, USA

Background

Biopharmaceuticals continue to represent the fastest growing segment of the global pharmaceutical industry. High throughput cell line selection and protein variants production have notably shortened the discovery and lead identification cycle for biologic drug development. Biologics

are generally not amenable to oral route delivery due to their intrinsic molecular properties. Injectable dosage forms have therefore become the common choice for initial commercial development. However, injections are invasive, and patient perception is generally less than pleasant, resulting in dosing compliance and market acceptability issues. In addition, competition from biosimilars (biogenerics) has increasingly become a reality. Consequently, development of various sustained release formulations and non-invasive delivery technologies has been a main focus of product enhancement and life-cycle management for many innovator biopharmaceuticals. The primary goal is generally to reduce injection frequencies as well as possibly improve safety and efficacy profiles at the same time. As regulatory guidelines for biologics are not as well established as for small molecule drugs, regulatory paths for development and approval of biologics are often more challenging.

Goals and Objectives

This program is designed to provide a comprehensive review of biologic drug development, commonly encountered issues, challenges, and recent advances in bioprocess, formulation, delivery, and manufacturing technologies. Detailed presentations will cover four development areas: biological drug substance and preformulation; formulation, delivery and process development; analytical technologies and PAT; and regulatory landscape and biosimilars. Each topic will include lectures from experts in the field followed by interactive group discussions and case studies in which

the audience is strongly encouraged to participate. Attendees are also encouraged to bring practical examples of issues and problems encountered at work for discussion and thought exchange, including success stories as well as lessons learned.

For more information, please visit
www.aapspharmaceutica.com/arden.

AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside

March 14–16, 2011
Bethesda North Marriott & Conference Center
Bethesda, MD, USA

Background

The area of drug transport continues to evolve rapidly, with advances in understanding the role of transport in drug absorption, distribution and excretion, as well as toxicity and disease; improvements in clinical translation of *in vitro* and preclinical transport studies; and increased regulatory expectations for understanding transport interactions (2010 EMA drug interaction draft guidance and 2010 ITC whitepaper). For the past decade, the AAPS Workshop on Drug Transporters has been the only recurring North American meeting dedicated to discussion of advances in this field and has a consistent record of relevance to pharmaceutical scientists. The 2011 workshop will continue to provide a venue for focused interactions with drug transport experts and thought leaders.

Objectives

The recognition of the influence of membrane transporters on drug disposition has driven a surge in drug transport-related research within the pharmaceutical sciences. Although considerable progress has been made over the past 15 years, the field of drug transport continues to evolve, particularly with respect to clinical translation of *in vitro*/preclinical data (2010 EMA drug interaction draft guidance and 2010 ITC whitepaper) and understanding systemic/tissue exposure implications, toxicity/disease pathogenesis, targeting transport for drug delivery, and interplay with metabolism. This fifth biennial AAPS Workshop on Drug Transporters aims to build on the success of previous meetings and provide a continued opportunity for pharmaceutical, academic and regulatory scientists to exchange ideas about the cutting-edge transporter research.

For more information, please visit
www.aapspharmaceutica.com/drugtrans.

Emerging Oral Delivery Strategies and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules

April 14–15, 2011
Sheraton Inner Harbor
Baltimore, MD, USA

Goals and Objectives

For small molecules, approximately 60–70% of NMEs are BCS II and IV, and there is increasing need for drug delivery technologies to enable the development of “drug-like” molecules in a timely and cost-effective manner. Proper biopharmaceutical and ADMET properties, along with adequate selectivity and potency, minimize subsequent failure risks and increase the chance that the most promising leads are advanced to development candidates. In the case of macromolecules (BCS III), intestinal permeability and metabolism are still the major barriers to overcome, with no commercial product on the market despite significant advancements over the last two decades. Proper selection and evaluation of a suitable drug delivery technology using proper *in vitro*/*in vivo* methodologies by considering the physicochemical and biopharmaceutical properties of the molecule/macromolecule are critical to the overall drug discovery and development strategy and success. This feature will be highlighted throughout the workshop and introduced by two keynote talks on new paradigms in drug discovery and development and emerging drug delivery technologies. It will then cover the following three areas: one on general drug development principles and considerations and two on specific drug delivery technologies and case studies: physicochemical and biopharmaceutical properties and evaluation tools, lipid-based systems and solid dispersions, and prodrugs and nanoparticles.

For more information, please visit
www.aapspharmaceutica.com/oraldelivery.

AAPS Workshop on Delivery and Disposition of Biotherapeutics across the Blood-Brain Barrier

May 14–15, 2010
Hilton San Francisco Union Square
San Francisco, CA, USA

Goals and Objectives

In recent years a significant effort has been guided toward the identification of novel therapeutic targets for central nervous system (CNS) disorders. However, these efforts have not translated into a robust success in developing biotherapeutic modalities for CNS diseases in the industry drug development pipeline. The primary reason is that the blood-brain barrier (BBB) isolates and protects CNS structures, creating a unique biochemically and immunologically privileged environment. Therefore, passage of macromolecules across this barrier is fraught with challenges. Further, even if 0.1 to 0.2% of any biotherapeutic drug modality crosses the BBB, there is no consensus in terms of method to be used or tissue/fluids to be collected for the optimum measurements of the therapeutic. In recent years, some technologies have evolved from academia or the small biotech industry that promise to deliver biotherapeutics in sufficient quantities. Although successful at the preclinical stage in lower vertebrates, none of these technologies have emerged in the clinical setting. What could be the issues stifling this progress? Investigators in academia as well as in industry have realized that there is a definite lack of proper communication channel that has prevented progress in the development of introduction of biotherapeutics across the BBB. Can we fix this?:

For more information, please visit

www.aapspharmaceutica.com/Biotherapeutics.

Upcoming AAPS Meetings

Log onto www.aapspharmaceutica.com/meetings for details.

► March 6 - 10, 2011

The 46th Annual Pharmaceutical Technologies Arden Conference: Pharmaceutical Development of Biologics: Fundamentals, Challenges, and Recent Advances

The Thayer Hotel, West Point, NY, USA

► March 14-16, 2011

AAPS Workshop on Drug Transporters in ADME: From the Bench to the Bedside

Bethesda N. Marriott & Conference Center, Bethesda, MD, USA

► April 14-15, 2011

AAPS Workshop on Emerging Oral Delivery Strategies and Technologies to Enable Biopharmaceutical Performance of BCS II, III and IV Molecules

Sheraton Inner Harbor Hotel, Baltimore, MD, USA

► May 14 - 15, 2010

AAPS Workshop on Delivery and Disposition of Biotherapeutics across the Blood Brain Barrier

Hilton San Francisco Union Square, San Francisco, CA, USA

► May 16-18, 2011

2011 AAPS National Biotechnology Conference

Hilton San Francisco Union Square, San Francisco, CA, USA

► October 23-27, 2011

2011 AAPS Annual Meeting and Exposition

Washington Convention Center

Washington, D.C., USA



AAPS Connection

2107 Wilson Blvd., Suite 700, Arlington, VA 22201-3042 USA, Ph: +1 703 243-2800

January 2011